Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.48 |
| ▸ | PPARA | Q07869 | 9/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968357 | 1.00 | PPARG (0.48) | PPARGPPARACYP2C9CYP2C19PPARD | |
| SCHEMBL25464401 | 0.87 | PPARG (0.46) | PPARGPPARACYP2C9CYP2C19PPARD | |
| SCHEMBL23319919 | 0.87 | PRKCZ (0.44) | CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL29967934 | 0.87 | PRKCZ (0.44) | CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL21296854 | 0.83 | HAO1 (0.44) | CYP2C9CYP2C19MCL1HDAC8HDAC6 | |
| SCHEMBL21296864 | 0.83 | PPARG (0.43) | PPARGPPARAACMSD | |
| SCHEMBL21312599 | 0.83 | ALPL (0.42) | — | |
| SCHEMBL21312600 | 0.83 | PPARG (0.43) | PPARGPPARAMCL1 | |
| SCHEMBL23319932 | 0.83 | CAMKK1 (0.42) | — | |
| SCHEMBL23319997 | 0.82 | DHODH (0.40) | PPARGPPARAHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | VENTHERA, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-3817816-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | Orfan Biotech Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112399873-A | Triazole glycolate oxidase inhibitor | 奥凡生物科技公司 | 2021-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | PPARG 914/4885PPARA 2155/4885CYP2C9 106/4885 |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | PPARG 914/4885PPARA 2155/4885CYP2C9 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.